134 related articles for article (PubMed ID: 31235395)
1. Intensity of Active Surveillance and Transition to Treatment in Men with Low-risk Prostate Cancer.
Olsson H; Nordström T; Clements M; Grönberg H; Lantz AW; Eklund M
Eur Urol Oncol; 2020 Oct; 3(5):640-647. PubMed ID: 31235395
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
Sathianathen NJ; Konety BR; Alarid-Escudero F; Lawrentschuk N; Bolton DM; Kuntz KM
Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
[TBL] [Abstract][Full Text] [Related]
3. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
[TBL] [Abstract][Full Text] [Related]
4. Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden.
Loeb S; Folkvaljon Y; Curnyn C; Robinson D; Bratt O; Stattin P
JAMA Oncol; 2017 Oct; 3(10):1393-1398. PubMed ID: 27768168
[TBL] [Abstract][Full Text] [Related]
5. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
6. Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer.
Van Hemelrijck M; Garmo H; Lindhagen L; Bratt O; Stattin P; Adolfsson J
Eur Urol; 2017 Oct; 72(4):534-541. PubMed ID: 27816297
[TBL] [Abstract][Full Text] [Related]
7. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
[TBL] [Abstract][Full Text] [Related]
8. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
9. Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
Beckmann K; Kinsella N; Olsson H; Wallerstedt Lantz A; Nordstrom T; Aly M; Adolfsson J; Eklund M; Van Hemelrijck M
BMC Urol; 2019 Aug; 19(1):73. PubMed ID: 31383015
[TBL] [Abstract][Full Text] [Related]
10. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
Womble PR; Montie JE; Ye Z; Linsell SM; Lane BR; Miller DC;
Eur Urol; 2015 Jan; 67(1):44-50. PubMed ID: 25159890
[TBL] [Abstract][Full Text] [Related]
11. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
[TBL] [Abstract][Full Text] [Related]
12. The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS).
Bratt O; Holmberg E; Andrén O; Carlsson S; Drevin L; Johansson E; Josefsson A; Nyberg M; Sandberg J; Stattin P; Robinsson D
Eur Urol; 2019 Oct; 76(4):461-466. PubMed ID: 30878303
[TBL] [Abstract][Full Text] [Related]
13. Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.
Inoue LYT; Lin DW; Newcomb LF; Leonardson AS; Ankerst D; Gulati R; Carter HB; Trock BJ; Carroll PR; Cooperberg MR; Cowan JE; Klotz LH; Mamedov A; Penson DF; Etzioni R
Ann Intern Med; 2018 Jan; 168(1):1-9. PubMed ID: 29181514
[TBL] [Abstract][Full Text] [Related]
14. Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years.
Preston MA; Feldman AS; Coen JJ; McDougal WS; Smith MR; Paly JJ; Carrasquillo R; Wu CL; Dahl DM; Barrisford GW; Blute ML; Zietman AI
Urol Oncol; 2015 Sep; 33(9):383.e9-16. PubMed ID: 26059076
[TBL] [Abstract][Full Text] [Related]
15. PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer: rationale and design.
Ahlberg MS; Adami HO; Beckmann K; Bertilsson H; Bratt O; Cahill D; Egevad L; Garmo H; Holmberg L; Johansson E; Rannikko A; Van Hemelrijck M; Jäderling F; Wassberg C; Åberg UWN; Bill-Axelson A
BMJ Open; 2019 Aug; 9(8):e027860. PubMed ID: 31444180
[TBL] [Abstract][Full Text] [Related]
16. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
17. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
18. Estimating the risks and benefits of active surveillance protocols for prostate cancer: a microsimulation study.
de Carvalho TM; Heijnsdijk EA; de Koning HJ
BJU Int; 2017 Apr; 119(4):560-566. PubMed ID: 27222299
[TBL] [Abstract][Full Text] [Related]
19. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.
Bul M; Zhu X; Valdagni R; Pickles T; Kakehi Y; Rannikko A; Bjartell A; van der Schoot DK; Cornel EB; Conti GN; Boevé ER; Staerman F; Vis-Maters JJ; Vergunst H; Jaspars JJ; Strölin P; van Muilekom E; Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2013 Apr; 63(4):597-603. PubMed ID: 23159452
[TBL] [Abstract][Full Text] [Related]
20. Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes.
Hussein AA; Welty CJ; Ameli N; Cowan JE; Leapman M; Porten SP; Shinohara K; Carroll PR
J Urol; 2015 Jul; 194(1):85-90. PubMed ID: 25623742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
